<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00452920</url>
  </required_header>
  <id_info>
    <org_study_id>20020358</org_study_id>
    <secondary_id>SCCC-2002058</secondary_id>
    <secondary_id>WIRB-20050719</secondary_id>
    <nct_id>NCT00452920</nct_id>
  </id_info>
  <brief_title>Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer</brief_title>
  <official_title>A Phase I/II Study of Docetaxel as a Radiosensitizer for Locally Advanced Cervical Cancer (GIA 13026)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells.&#xD;
      Docetaxel may make tumor cells more sensitive to radiation therapy. Giving docetaxel together&#xD;
      with radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of docetaxel when&#xD;
      given together with radiation therapy and to see how well they work in treating patients with&#xD;
      stage II, stage III, or stage IV cervical cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the recommended phase II dose (RPTD) of docetaxel when administered with&#xD;
           radiotherapy in patients with stage IIB-IVA cervical cancer. (Phase I)&#xD;
&#xD;
        -  Assess the progression-free survival of patients treated with this regimen. (Phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety, feasibility, and toxicity of this regimen in these patients.&#xD;
           (Phase I)&#xD;
&#xD;
        -  Assess the toxicity of this regimen at the RPTD in these patients. (Phase II)&#xD;
&#xD;
        -  Determine the response in patients treated with this regimen. (Phase II)&#xD;
&#xD;
      OUTLINE: This is a phase I, nonrandomized, prospective, dose-escalation study of docetaxel&#xD;
      followed by an open-label phase II study.&#xD;
&#xD;
        -  Phase I: Patients receive docetaxel IV over 30 minutes on day 1. Treatment repeats&#xD;
           weekly for up to 6 courses in the absence of disease progression or unacceptable&#xD;
           toxicity. Patients also undergo concurrent pelvic external-beam radiotherapy (EBRT) once&#xD;
           daily 5 days a week for 5 weeks. Beginning 1-2 weeks after completion of EBRT, patients&#xD;
           receive one or two applications of intracavitary low-dose-rate brachytherapy (LDR BT)&#xD;
           comprising cesium-137.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of docetaxel until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity. The recommended phase II dose (RPTD) is the&#xD;
      dose below the MTD.&#xD;
&#xD;
        -  Phase II: Patients receive docetaxel at the RPTD, EBRT, and LDR BT as in phase I.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 2 years, every&#xD;
      6 months for 3 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 72 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended phase II dose (Phase I)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (Phase II)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response (Phase II)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (Phase II)</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Cervical Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>cesium Cs 137</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed squamous cell carcinoma of the uterine&#xD;
             cervix&#xD;
&#xD;
               -  Locally advanced (stage IIB- IVA) disease&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by&#xD;
             conventional techniques OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN) if alkaline phosphatase (AP) ≤&#xD;
             ULN OR AP ≤ 4 times ULN if SGOT and SGPT ≤ ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for up to 6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No history of severe allergic reactions to agents containing polysorbate 80&#xD;
&#xD;
          -  No concurrent uncontrolled illness including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness or social situations that would preclude compliance with&#xD;
                  study requirements&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 4 weeks since prior unrelated therapy and recovered&#xD;
&#xD;
          -  No prior chemotherapy or pelvic radiotherapy&#xD;
&#xD;
          -  No other concurrent investigational agents or anticancer agents or therapies&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A. Lucci, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami Sylvester Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>March 27, 2007</study_first_submitted>
  <study_first_submitted_qc>March 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2007</study_first_posted>
  <last_update_submitted>December 14, 2016</last_update_submitted>
  <last_update_submitted_qc>December 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervical squamous cell carcinoma</keyword>
  <keyword>stage IIB cervical cancer</keyword>
  <keyword>stage III cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

